- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 28, Issue 2, 2022
Current Pharmaceutical Design - Volume 28, Issue 2, 2022
Volume 28, Issue 2, 2022
-
-
An Assessment of In-vitro and In-vivo Evaluation Methods for Theranostic Nanomaterials
Authors: Poonam Parashar, Neelu Singh, Alka, Priyanka Maurya and Shubhini A. SarafNanoparticles (NPs) as nanocarriers have emerged as novel and promising theranostic agents. The term theranostics revealed the properties of NPs capable of diagnosing the disease at an early stage and/or treating the disease. Such NPs are usually developed employing a surface engineering approach. The theranostic agents comprise NPs loaded with a drug/diagnostic agent that delivers it precisely to the target si Read More
-
-
-
Theranostic Applications of Nanomaterials in the Field of Cardiovascular Diseases
Authors: Rakesh K. Sahoo, Himani Singh, Kamlesh Thakur, Umesh Gupta and Amit K . GoyalA large percentage of people are being exposed to mortality due to cardiovascular diseases. Convention approaches have not provided satisfactory outcomes in the management of these diseases. To overcome the limitations of conventional approaches, nanomaterials like nanoparticles, nanotubes, micelles, lipid-based nanocarriers, dendrimers, and carbon-based nanoformulations represent the new aspect of diagnosis a Read More
-
-
-
Nanotherapeutics and Nanotheragnostics for Cancers: Properties, Pharmacokinetics, Biopharmaceutics, and Biosafety
With the increasing worldwide rate of chronic diseases, such as cancer, the development of novel techniques to improve the efficacy of therapeutic agents is highly demanded. Nanoparticles are especially well suited to encapsulate drugs and other therapeutic agents, bringing additional advantages, such as less frequent dosage requirements, reduced side effects due to specific targeting, and therefore increased patient Read More
-
-
-
Theranostic Applications of Nanomaterials in Alzheimer’s Disease: A Multifunctional Approach
Authors: Priyanka Tripathi, Poonam Shukla and Erhard BieberichThe blood-brain barrier (BBB) prevents the transfer of many therapeutic drugs across the brain. Therefore, the leading treatment strategies of Alzheimer’s disease (AD) are often unsuccessful. Another challenge is to achieve specific targetability across BBB and diagnosis. Herein, theranostic-based strategies are emerging in order to combine therapeutic, targeting, and diagnostic capabilities. Recent nanotechnolo Read More
-
-
-
Recent Advances in Theranostic Applications of Nanomaterials in Cancer
Authors: Faraha Ahmed, Mohammad A. Khan, Nafis Haider, Mohammad Zaki Ahmad and Javed AhmadEarly detection and accurate monitoring are two critical factors affecting the outcome of anticancer therapy. However, both these factors are affected by the limitations of conventional approaches of diagnosis and treatment. Nanomedicine has progressively offered a scientific solution in improved delivery and better diagnosis of various cancers, thus providing a targeted treatment approach. With the advances in the field Read More
-
-
-
Recent Developments in Mesoporous Silica Nanoparticles for Tumor Theranostic Applications
Authors: Xuerui Wang, Mengyuan Zheng, Faisal Raza, Yuhao Liu, Yiqi Wei, Mingfeng Qiu and Jing SuDue to the advantages of adjustable pore size, easy surface modification, high biocompatibility, and so on, mesoporous silica nanoparticles (MSNs) have attracted significant attention. Moreover, they are widely used in the fields of biology and medical research, mostly focusing on drug and gene delivery and bioimaging. This review introduces several commonly used synthetic methods of MSNs and the latest progress of MSNs in t Read More
-
-
-
Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape
Authors: Rishi Paliwal, Pramod Kumar, Akash Chaurasiya, Rameshroo Kenwat, Sumeet Katke and Shivani R. PaliwalBackground: Nanopharmaceuticals serve as emerging forms of modern medicines, which include nanomedicines, nanosimilars, nanotheranostics, nanodevices, and many more. In the last two decades, a large number of nano-based products have reached the market and are being used clinically. Objectives: Unlike conventional pharmaceutical products, nanopharmaceuticals behave differently both in vitro and in vivo, and Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
- Issue 46
- Issue 45
- Issue 44
- Issue 43
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
